Advertisement

Breast Cancer Research and Treatment

, Volume 35, Issue 1, pp 115–132 | Cite as

Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research

  • H. Shelton Earp
  • Thomas L. Dawson
  • Xiong Li
  • Hong Yu
Article

Summary

The EGF receptor (EGFR) and HER2 are members of a growth factor receptor family. Overexpression of either protein in advanced breast cancer correlates with poor prognosis. EGF stimulates growth by binding to EGFR, activating the receptor's intracellular tyrosine kinase. The initial consequence is phosphorylation of specific tyrosine-containing sequences in the receptor's carboxyl terminus. These phosphotyrosines serve as high affinity recognition sites for proteins that, in turn, transmit the growth signal inside the cell. Mechanistic studies suggest that EGF binds to a single EGFR, triggering dimerization with another like receptor molecule. This dimerization is thought to initiate the tyrosine kinase activation.

The EGF receptor family was recently expanded with the sequencing of HER3 and HER4. Each of the four family members was postulated to regulate a unique growth or differentiation signaling repertoire when activated by a receptor-specific ligand. However, new data from numerous laboratories suggest that EGFR family members may play a complex and ultimately more flexible role in signaling by forming heterodimers between family members, e.g. EGFR:HER2 or HER4:HER2. These heterodimers may form even when only one member of the pair binds its ligand.

This review summarizes current work on heterodimerization and attempts to predict the consequences for downstream signaling. In brief, when compared to ligand-dependent receptor homodimers comprised of two proteins with the same internalization sequence and phosphorylated tyrosine residues, heterodimers are likely to: i) expand substrate selection and downstream signaling pathway activation; ii) promote interaction between sets of substrates in the mixed receptor complexes that would not ordinarily be physically juxtaposed; iii) alter the duration of receptor signaling by changing rates of receptor internalization, ligand loss, kinase inactivation, recycling, etc.; and iv) alter rates of receptor and substrate dephosphorylation. In addition to understanding interactions of heterodimers with the internalization machinery, identification of receptor-specific substrates and binding proteins for each EGFR family member will be necessary to explicate the role of heterodimers in growth and differentiation.

Key words

EGF receptor HER2 HER3 HER4 heterodimerization tyrosine phosphorylation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bishop JM: Molecular themes in oncogenes. Cell 64: 235–248, 1991Google Scholar
  2. 2.
    Schlessinger J, Ullrich A: Growth factor signaling by receptor tyrosine kinases. Neuron 9:383–391, 1992Google Scholar
  3. 3.
    Carpenter G, Wahl MI: The epidermal growth factor family. Peptide Growth Factors & Their Receptors 1:69–171, 1990Google Scholar
  4. 4.
    Fantl WJ, Johnson DE, Williams LT: Signaling by receptor tyrosine kinases. Annu Rev Biochem 62:453–481, 1993Google Scholar
  5. 5.
    Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S: Oncogenes and signal transduction. Cell 64:281–302, 1991Google Scholar
  6. 6.
    Hunter T, Karin M: The regulation of transcription by phosphorylation. Cell 70:375–387, 1992Google Scholar
  7. 7.
    Crews CM, Erikson RL: Extracellular signals and reversible protein phosphorylation: What to make of it all. Cell 74:215–217, 1993Google Scholar
  8. 8.
    Schlessinger J: How Receptor Tyrosine Kinases Activate Ras. Elsevier Science Publishers, UK, 1993, pp 273–275Google Scholar
  9. 9.
    Hunter T, Cooper JA: Protein-tyrosine kinases. Ann Rev Biochem 54:897–930, 1985Google Scholar
  10. 10.
    Hanks SK, Quinn AM: Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Meth Enzymol 200:38–62, 1991Google Scholar
  11. 11.
    Wilks AF: Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci USA 86:1603–1607, 1989Google Scholar
  12. 12.
    Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD: Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307: 521–527, 1984Google Scholar
  13. 13.
    Bolen JB: Nonreceptor tyrosine protein kinases. Oncogene 8:2025–2031, 1993Google Scholar
  14. 14.
    Bolen JB, Rowley RB, Spana C, Tsygankov AY: The Src family of tyrosine protein kinases in hemopoietic signal transduction. FASEB J 6:3403–3409, 1992Google Scholar
  15. 15.
    Weiss A: T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein-tyrosine kinases. Cell 73:209–212, 1993Google Scholar
  16. 16.
    Chan AC, Iwashima M, Turck CW, Weiss A: ZAP-70: a 70 kD protein-tyrosine kinase that associates with the TCRς chain. Cell 71:649–662, 1992Google Scholar
  17. 17.
    de Weers M, Verschuren MCM, Kraakman MEE, Mensink RGJ, Schuurman RKB, van Dongen JJM, Hendriks RW: The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages. Eur J Immunol 23: 3109–3114, 1993Google Scholar
  18. 18.
    O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R, Le BMM, Earp HS, Liu ET: axl: a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11: 5016–5031, 1991Google Scholar
  19. 19.
    Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS: Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ 5:647–657, 1994Google Scholar
  20. 20.
    Jardines L, Weiss M, Fowble B, Greene M: neu (c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 61:268–282, 1993Google Scholar
  21. 21.
    Peles E, Yarden Y: Neu and its ligands: from an oncogene to neural factors. BioEssays 15:815–824, 1993Google Scholar
  22. 22.
    Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and S-phase activity predict response to adjuvant therapy in women with node positive early breast cancer. New Engl J Med 330:1260–1266, 1994Google Scholar
  23. 23.
    Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86:9193–9197, 1989Google Scholar
  24. 24.
    Plowman GD, Culouscou J-M, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M: Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90:1746–1750, 1993Google Scholar
  25. 25.
    Pawson T, Gish GD: SH2 and SH3 domains: from structure to function. Cell 71:359–362, 1992Google Scholar
  26. 26.
    Birge RB, Hanafusa J: Closing in on SH2 specificity. Science 262:1522–1524, 1993Google Scholar
  27. 27.
    Fry MJ, Panayotou G, Booker GW, Waterfield MD: New insights into protein-tyrosine kinase receptor signaling complexes. Protein Science 2:1785–1797, 1993Google Scholar
  28. 28.
    McCune BK, Hickle WR, Earp HS: The role of endocytosis in epidermal growth factor signaling complexes. Advances in Cell and Molecular Biology of Membranes, Vol. 1, pp 269–305, 1993Google Scholar
  29. 29.
    Walton KM, Dixon JE: Protein tyrosine phosphatases. Annu Rev Biochem 62:101–20, 1993Google Scholar
  30. 30.
    Fischer EH, Charbonneau H, Tonks NK: Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. Science 253:401–406, 1991Google Scholar
  31. 31.
    Carpenter G, Cohen S: Epidermal growth factor. Ann Rev Biochem 48:193–216, 1979Google Scholar
  32. 32.
    Birchmeier C, Sonnenberg E, Weidner KM, Walter B: Tyrosine kinase receptors in the control of epithelial growth and morphogenesis during development. Bio-Essays 15:185–190, 1993Google Scholar
  33. 33.
    Horvitz R, Sternberg PW: Multiple intercellular signaling systems control the development of theCaenorhabditis elegans vulva. Nature 351:535–541, 1991Google Scholar
  34. 34.
    Doyle HJ, Bishop JM: Torso, a receptor tyrosine kinase required for embryonic pattern formation, shares substrates with the Sevenless and EGF-R pathways in Drosophila. Genes Devel 7:633–646, 1993Google Scholar
  35. 35.
    Bargmann CI, Hung M-C, Weinberg RA: Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649–657, 1986Google Scholar
  36. 36.
    Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI: The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9:2109–2123, 1994Google Scholar
  37. 37.
    Coussens L, Yang-Feng TL, Liao Y-C, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139, 1985Google Scholar
  38. 38.
    Semba K, Kamata N, Toyoshima K, Yamamoto T: A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497–6501, 1985Google Scholar
  39. 39.
    King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974–976, 1985Google Scholar
  40. 40.
    Lax I, Bellot F, Howk R, Ullrich A, Givol D, Schlessinger J: Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules. EMBO J 8:421–427, 1989Google Scholar
  41. 41.
    Wu D, Wang L, Chi Y, Sato G, Sato JD: Human epidermal growth factor receptor residue covalently crosslinked to epidermal growth factor. Proc Natl Acad Sci USA 87:3151–3155, 1990Google Scholar
  42. 42.
    Carraway KL III, Cantley LC: A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78:5–8, 1994Google Scholar
  43. 43.
    Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway III KL: Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 91:8132–8136, 1994Google Scholar
  44. 44.
    Kraus MH, Fedi P, Starks V, Muraro R, Aaronson SA: Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Proc Natl Acad Sci USA 90:2900–2904, 1993Google Scholar
  45. 45.
    Soltoff SP, Carraway KL III, Prigent SA, Gullick WG, Cantley LC: ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 14:3550–3558, 1994Google Scholar
  46. 46.
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712, 1989Google Scholar
  47. 47.
    Gasparini G, Gullick WJ, Bevilacqua P, Sainsbury JRC, Meli S, Boracchi P, Testolin A, LaMalfa G, Pozza F: Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10:686–695, 1992Google Scholar
  48. 48.
    Liu E, He M, Barcos M, Thor A, Benz CC: High frequency of HER-2/neu amplification inin situ carcinoma of the breast: analysis using differential polymerase chain reaction. Oncogene 7:1027–1032, 1992Google Scholar
  49. 49.
    Lippman ME, Dickson RB: Mechanisms of growth control in normal and malignant breast epithelium. Recent Progr Horm Res 45:383–440, 1989Google Scholar
  50. 50.
    Osborne CK, Arteaga CL: Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Res Treat 15:3–11, 1990Google Scholar
  51. 51.
    Dickson RB: Stimulatory and inhibitory growth factors and breast cancer. J Steroid Biochem Molec Biol 37:795–803, 1990Google Scholar
  52. 52.
    LeJeune S, Leek R, Horak E, Plowman G, Greenall M, Harris AL: Amphiregulin, epidermal growth factor receptor, and estrogen receptor expression in human primary breast cancer. Cancer Res 53:3597–3602, 1993Google Scholar
  53. 53.
    Earp HS, Austin KS, Blaisdell J, Rubin RA, Nelson KG, Lee LW, Grisham JW: Epidermal growth factor (EGF) stimulates EGF receptor synthesis. J Biol Chem 261:4777–4780, 1986Google Scholar
  54. 54.
    Clark AJL, Ishii S, Richert N, Merlino GT, Pastan I: Epidermal growth factor regulates the expression of its own receptor. Proc Natl Acad Sci USA 82:8374–8378, 1985Google Scholar
  55. 55.
    Kudlow JE, Cheung C-YM, Bjorge JD: Epidermal growth factor stimulates the synthesis of its own receptor in a human breast cancer cell line. J Biol Chem 261:4134–4138, 1986Google Scholar
  56. 56.
    Earp HS, Hepler JR, Petch LA, Miller A, Berry AR, Harris J, Raymond VW, McCune BK, Lee LW, Grisham JW, Harden TK: Epidermal growth factor (EGF) and hormones stimulate phosphoinositide hydrolysis and increase EGF receptor protein synthesis and mRNA levels in rat liver epithelial cells. J Biol Chem 263:13868–13874, 1988Google Scholar
  57. 57.
    Wada T, Qian X, Greene MI: Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61:1339–1347, 1990Google Scholar
  58. 58.
    Goldman R, Ben-Levy R, Peles E, Yarden Y: Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochem 29:11024–11028, 1990Google Scholar
  59. 59.
    Plowman GD, Green JM, Culouscou J-M, Carlton GW, Rothwell VM, Buckley S: Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 366:473–475, 1993Google Scholar
  60. 60.
    Carraway KL III, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A, Diamonti AJ, Vandlen RL, Cantley LC, Cerione RA: The erbB3 gene product is a receptor for heregulin. J Biol Chem 269:14303–14306, 1994Google Scholar
  61. 61.
    Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway KL III: Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269:14661–14665, 1994Google Scholar
  62. 62.
    Dougall WC, Qian X, Greene MI: Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy. J Cell Biochem 53:61–73, 1993Google Scholar
  63. 63.
    Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI: A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 339:230–231, 1989Google Scholar
  64. 64.
    Carraway KL III, Cerione RA: Inhibition of epidermal growth factor receptor aggregation by an antibody directed against the epidermal growth factor receptor extracellular domain. J Biol Chem 268:23860–23867, 1993Google Scholar
  65. 65.
    Lee J, Dull TJ, Lax I, Schlessinger J, Ullrich A: HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. EMBO J 8:167–173, 1989Google Scholar
  66. 66.
    Lehväslaiho J, Lehtola L, Sistonen L, Alitalo K: A chimeric EGF-R neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation. EMBO J 8:159–166, 1989Google Scholar
  67. 67.
    Velu TJ, Beguinot L, Vass WC, Willingham MC, Merlino GT, Pastan I, Lowy DR: Epidermal growth factor-dependent transformation by a human EGF receptor proto-oncogene. Science 238:1408–1410, 1987Google Scholar
  68. 68.
    DiFiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J, Aaronson SA: Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH3T3 cells. Cell 51:1063–1070, 1987Google Scholar
  69. 69.
    Marco ED, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson SA, DiFiore PP: Autocrine interaction between TGFα and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4:831–838, 1989Google Scholar
  70. 70.
    Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Ben-Levy R, Yarden Y: Isolation of the neu/HER2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69:205–216, 1992Google Scholar
  71. 71.
    Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab J, Lewis GD, Shepard HM, Kuang W-J, Wood WI, Goeddel DV, Vandlen RL: Identification of heregulin, a specific activator of p180erbB2. Science 256:1205–1210, 1992Google Scholar
  72. 72.
    Falls DL, Rosen KM, Corfas G, Lane WS, Fischbach GD: ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. Cell 72:801–815, 1993Google Scholar
  73. 73.
    Marchionni MA, Goodearl ADJ, Chen MS, Bermingham-McDonogh O, Kirk C, Hendricks M, Danehy F, Misumi D, Sudhalter J, Kobayashi K, Wroblewski D, Lynch C, Baldassare M, Hiles I, Davis JB, Hsuan JJ, Totty NF, Otsu M, McBurney RN, Waterfield MD, Stroobant P, Gwynne D: Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362:312–318, 1993Google Scholar
  74. 74.
    Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D, Yarden Y: Cell-type specific interaction of neu differentiation factor (NDF/heregulin) with neu/HER2 suggests complex ligand-receptor relationships. EMBO J 12:961–971, 1993Google Scholar
  75. 75.
    Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J: Mechanism of activation of the TGFβ receptor. Nature 370:341–347, 1994Google Scholar
  76. 76.
    Givol D, Yayon A: Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 6:3362–3369, 1992Google Scholar
  77. 77.
    Lupu R, Colomer R, Zugmaier G, Sarup J, Shepard M, Slamon D, Lippman ME: Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science 249:1552–1555, 1990Google Scholar
  78. 78.
    Samanta A, LeVea CM, Dougall WC, Qian X, Greene MI: Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci USA 91:1711–1715, 1994Google Scholar
  79. 79.
    Qian X, LeVea CM, Freeman JK, Dougall WC, Greene MI: Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc Natl Acad Sci USA 91: 1500–1504, 1994Google Scholar
  80. 80.
    Kashles O, Yarden Y, Fischer R, Ullrich A, Schlessinger J: A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Mol Cell Biol 11:1454–1463, 1991Google Scholar
  81. 81.
    White MF, Kahn CR: The insulin signaling system. J Biol Chem 269:1–4, 1994Google Scholar
  82. 82.
    Marengere LEM, Songyang Z, Gish GD, Schallers MD, Parsons JT, Stern MJ, Cantley LC, Pawson T: SH2 domain specificity and activity modified by a single residue. Nature 369:502–505, 1994Google Scholar
  83. 83.
    Batzer AG, Rotin D, Skolnik EY, Schlessinger J: Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol 14: 5192–5201, 1994Google Scholar
  84. 84.
    Songyang Z, Schoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, King F, Roberts T, Ratnofsky S, Lechleider RJ, Neel BG, Birge RB, Fajardo JE, Chou MM, Hanafusa H, Schaffhausen B, Cantley LC: SH2 domains recognize specific phosphopeptide sequences. Cell 72:767–778, 1993Google Scholar
  85. 85.
    Songyang Z, Schoelson SE, McGlade J, Olivier P, Pawson T, Bustelo XR, Barbacid M, Sabe H, Hanafusa H, Yi T, Ren R, Baltimore D, Ratnofsky S, Feldman RA, Cantley, LC: Specific motifs recognized by the SH2 domains of csk, 3BP2, fps/fes, GRB-2, HCP, SHC, syk, and vav. Mol Cell Biol 14:2777–2785, 1994Google Scholar
  86. 86.
    Cooper JA, Kashishian A: In vivo binding properties of SH2 domains from GTPase activating protein and phosphatidylinositol 3-kinase. Mol Cell Biol 13:1737–1745, 1993Google Scholar
  87. 87.
    Feng G-S, Pawson T: Phosphotyrosine phosphatases with SH2 domains: regulators of signal transduction. Trends Genet 10:54–58, 1994Google Scholar
  88. 88.
    Sorkin A, DiFiore PP, Carpenter G: The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. Oncogene 8: 3021–3028, 1993Google Scholar
  89. 89.
    Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN, Rosenfeld MG: Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science 247:962–964, 1990Google Scholar
  90. 90.
    Traverse S, Gomez N, Paterson H, Marshall C, Cohen P: Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Biochem J 288:351–355, 1992Google Scholar
  91. 91.
    Peraldi P, Scimeca JC, Van Oberghen E: Regulation of extracellular signal-regulated protein kinase-1 (ERK-1; pp44/mitogen-activated protein kinase) by epidermal growth factor and nerve growth factor in PC12 cells: implication of ERK1 inhibitory activities. Endocrinology 132:2578–2585, 1993Google Scholar
  92. 92.
    Segatto O, Pelicci G, Giuli S, Digiesi G, DiFiore PP, McGlade J, Pawson T, Pelicci PG: Shc products are substrates of erbB-2 kinase. Oncogene 8:2105–2112, 1993Google Scholar
  93. 93.
    Stein D, Wu J, Fuqua SAW, Roonprapunt C, Yajnik V, D'Eustachio P, Moskow JJ, Buchberg AM, Osborne CK, Margolis B: The SH2 domain protein GRB-7 is co-amplified, overexpressed, and in a tight complex with HER2 in breast cancer. EMBO J 13:1331–1340, 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • H. Shelton Earp
    • 1
  • Thomas L. Dawson
    • 1
  • Xiong Li
    • 1
  • Hong Yu
    • 1
  1. 1.Departments of Medicine and PharmacologyUniversity of North Carolina, and the UNC Lineberger Comprehensive Cancer CenterUSA

Personalised recommendations